Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

As previously presented, gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet”) and gedatolisib + fulvestrant ('gedatolisib doublet”) reduced the risk of disease progression or death versus ...

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper deal and raising £8.5 million.

We look at the clinical stories patients might be reading in the mainstream news media and provide the original evidence ...

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that ...

Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: MELBOURNE, Australia and INDIANAPOLIS ...

Strong capital position of $667.2 million in cash, cash equivalents and short-term investments, together with $180 million in anticipated collaboration payments, expected to support advancement of ...

(brizmaker/GettyImages) Multivitamins have ignited a fierce scientific debate over whether nutritional supplements are beneficial to our health or a multi-billion-dollar racket. A long-term randomized ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...